ACC: AI-Based Video Biomarker Detects Aortic Stenosis Progression
By Elana Gotkine HealthDay Reporter
MONDAY, April 8, 2024 -- A video-based artificial intelligence (AI) biomarker (Digital Aortic Stenosis [AS] Severity index [DASSi]) can detect severe AS development and progression among patients undergoing echocardiography or cardiac magnetic resonance imaging, according to a study published online April 6 in JAMA Cardiology to coincide with the annual meeting of the American College of Cardiology, held from April 6 to 8 in Atlanta.
Evangelos K. Oikonomou, M.D., D.Phil., from the Yale School of Medicine in New Haven, Connecticut, and colleagues deployed DASSi to patients with no AS or with mild-to-moderate AS at baseline to identify development and progression of AS in a cohort study. A total of 12,599 participants were included in the echocardiographic study: 8,798 from the Yale New Haven Health System (YNHHS) and 3,801 from the Cedars-Sinai Medical Center (CSMC).
The researchers found that higher baseline DASSi was associated with faster progression in aortic valve velocity (AV-Vmax; per 0.1 DASSi increment, 0.033 and 0.082 m/s per year in YNHHS and CSMC, respectively), with values of 0.2 or greater associated with a fourfold to fivefold higher aortic valve replacement risk compared with values of <0.2 (adjusted hazard ratios [95 percent confidence intervals], 4.97 [2.71 to 5.82] and 4.04 [0.92 to 17.70] for YNHHS and CSMC, respectively), independent of confounding variables of age, sex, race, ethnicity, ejection fraction, and AV-Vmax. The findings were reproduced in 45,474 participants undergoing cardiac magnetic resonance imaging in the U.K. Biobank.
"Our study defines novel AI-based videographic phenotyping of cardiac anatomy and function to detect distinct clinical trajectories among patients with no or nonsevere AS, which generalize across multinational cohorts and noninvasive modalities," the authors write.
Several authors disclosed ties to the pharmaceutical industry, one author disclosed a related patent, and one author disclosed payments from law firms.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States
THURSDAY, Oct. 31, 2024 -- Early-onset colorectal cancer (EO-CRC) mortality rose in the United States over the past two decades, most notably in patients aged 20 to 44 years...
Early Aortic Valve Intervention Not Beneficial for Severe Aortic Stenosis
THURSDAY, Oct. 31, 2024 -- For patients with asymptomatic severe aortic stenosis and myocardial fibrosis, early aortic valve intervention does not impact all-cause death or...
Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening
WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.